Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 199.20

+0.1%

Nov 21 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Henry Niman who wrote (10476)	10/30/1997 11:41:00 PM
From: squetch	Read Replies (1) of 32384

My quick take of the stuff I read In CTCL if patients had a high affinity for IL-2 receptors there was a positive response. Side effects didn't seem severe. In psoriasis it also seemed to show improvements. In an open label dose escalation study mean disease severity declined steadily from baseline. In 12/95 they had to stop a trial b/c a patient experienced unexpected blood clotting. FDA allowed restart. Seemed good in psoriasis which has $3B spent in US. Current treatments have toxic side effects. In one double blind placebo trial for RA, which curoiusly is a side effect of severe psoriasis, results were not stat sig. SRGN blamed the improvement on the control group. Company notes patents issued to NCI 4,892,827 and 5,082,927 which competitors have/may be using.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next